Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: tyrosine kinase inhibitors - Onconova

Drug Profile

Research programme: tyrosine kinase inhibitors - Onconova

Alternative Names: Bcr-Abl/JAK2 inhibitors - Onconova; HER1 inhibitors - Onconova; HER2 inhibitors - Onconova; HER2-inhibitors; ON 150030; ON01135; ON012380; ON01370; ON044580; ON045270; ON128030; ON128060

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Onconova Therapeutics
  • Class Benzene derivatives; Pyrimidines; Quinazolines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Protein tyrosine kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 08 Sep 2010 Preclinical development is ongoing in USA
  • 08 Sep 2010 Research programme: tyrosine kinase inhibitors - Onconova is available for licensing as of 08 Sep 2010. http://www.onconova.com/partneringopportunities.shtml
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top